B2036 PEG IN ACROMEGALY

B2036 肢端肥大症中的 PEG

• 批准号: 6305848
• 负责人: DAVID L KLEINBERG
• 金额: $ 2.1万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6305848
• 关键词: acromegaly; biological signal transduction; clinical research; drug adverse effect; drug screening /evaluation; endocrine disorder chemotherapy; hormone inhibitor; hormone receptor; human subject; human therapy evaluation; insulinlike growth factor; placebos; polyethylene glycols; skeletal disorder chemotherapy; somatotropin

This randomized, double-blind, placebo controlled, study of B2036-PEG will attempt to determine the tolerability and efficacy of this drug in the subjects with acromegaly. B2036-PEG is a growth hormone receptor antagonist which will reversibly bind to the growth hormone receptor, blocking signal tranduction, and lead to reductions in circulating IGF-1.

这项B2036-PEG的随机、双盲、安慰剂对照研究将试图确定该药物在肢端肥大症受试者中的耐受性和疗效。B2036-PEG是一种生长激素受体拮抗剂，可与生长激素受体可逆结合，阻断信号转导，导致循环IGF-1减少。